Tuesday, February 05, 2019 by: Zoey Sky Tags: badcancer, badhealth, cancer causes, cancer progression, drug response, genes, genetic mutation, lung cancer (Natural News) Deadly lung cancers were found to be the result of multiple genetic changes, according to a study led by researchers from the University of San Francisco (UCSF). The UCSF team’s findings imply that new first-line combination therapies are necessary to treat the full array of mutations that can worsen a patient’s cancer and thwart drug resistance. Trever Bivona, M.D., Ph.D., a UCSF Medical Center oncologist, said, “Currently we treat patients as if different oncogene mutations are mutually exclusive. If you have an EGFR mutation we treat you with one class of drugs, and if you have a KRAS mutation we pick a different class of drugs. Now we see such mutations regularly coexist, and so we need to adapt our approach to treatment.” Lung cancer is currently the leading cause … [Read more...] about Cause of cancer found to be more complex than previously thought: Lung cancer results from gene mutations that appear to work together
Non small cell stage 4 lung cancer
Former Olympic hockey player says radon caused stage 4 four lung cancer
close Video Former Olympic hockey player on how she developed lung cancer from the radon levels in her home Research shows radon, an odorless gas that can seep into your home, is associated with lung cancer. 33-year-old Olympian Rachael Malmberg shares her story and awareness on how the high levels of radon in her family homes caused her to develop stage 4 lung cancer. It's the second leading cause of lung cancer. And you don't even know when it's present: radon. It’s an odorless tasteless gas that seeps up through the ground and diffuses into the air—and often times, right into your home. Rachael Malmberg, a former member of the U.S. Women’s ice hockey Olympic team had no idea her childhood and current home had dangerous levels of radon until it was too late, and she was diagnosed with stage 4 lung cancer. “It wasn't on my radar at all actually until I started doing research on causes of lung cancer. Upon diagnosis I had no idea about … [Read more...] about Former Olympic hockey player says radon caused stage 4 four lung cancer
Merck’s Keytruda extends lung cancer survival in two trials
CHICAGO (Reuters) - Merck & Co’s immunotherapy Keytruda improved survival as a stand-alone treatment for newly-diagnosed lung cancer patients and with chemotherapy for hard-to-treat squamous cell lung cancer, new data released on Sunday showed, further cementing the company’s lead in the most lucrative oncology market. FILE PHOTO: A giant inflatable pair of lungs is seen in front of the European Parliament in Strasbourg, December 10, 2013. REUTERS/Vincent Kessler Keytruda is competing with drugs from Roche, Bristol-Myers Squibb and others that also unleash the body’s immune system to attack tumors for dominance in lung cancer. They have racked up approvals for a variety of cancers, but newly-diagnosed lung cancer is seen as the biggest commercial opportunity. The new results, presented at the American Society for Clinical Oncology (ASCO) meeting in Chicago, add to the view that Keytruda has “set the floor against which other therapies will need … [Read more...] about Merck’s Keytruda extends lung cancer survival in two trials
Merck’s Keytruda Shown to Extend Lung Cancer Survival in Two Trials
New trial results show that Merck & Co's Keytruda improves survival as a stand-alone treatment for newly diagnosed lung cancer and in combination with chemotherapy for hard-to-treat squamous cell lung cancer. The results, presented at the annual meeting of the American Society for Clinical Oncology in Chicago, add to the argument that Keytruda has "set the floor against which other therapies will need to be compared," Roy Baynes, head of clinical development at Merck, told Reuters. Keytruda, along with drugs like Roche's Tecentriq and Bristol-Myers Squibb's Opdivo, is designed to unleash the body’s immune system to attack cancer cells. One trial involved 1,274 patients with advanced non-small cell lung cancer who tested positive for the PDL1 protein targeted by Keytruda. It showed that Keytruda patients lived for a median of 16.7 months, compared with 12.1 percent for patients given chemotherapy. Patient outcomes were linked to the biomarker. Keytruda patients with PDL1 … [Read more...] about Merck’s Keytruda Shown to Extend Lung Cancer Survival in Two Trials
Roche, chasing Merck, notches another lung cancer win
ZURICH (Reuters) - Roche’s bid to keep Merck’s cancer blockbuster Keytruda within striking distance got a lift on Tuesday when the Swiss drugmaker said its immunotherapy Tecentriq mixed with chemotherapy boosted lung cancer patients’ survival. FILE PHOTO: Swiss drugmaker Roche's logo is seen at their headquarters in Basel, Switzerland January 28, 2016. REUTERS/Arnd Wiegmann/File Photo Its phase III IMpower130 study, one of eight trials it has going against lung cancer that rely on Tecentriq, met goals of boosting overall survival and progression-free survival in the initial treatment of advanced non-squamous non-small cell lung cancer (NSCLC) compared to chemotherapy alone, Roche said. This is the third late-stage study of Tecentriq alone or in a cocktail to show an overall survival benefit for people with NSCLC, Roche said. Roche’s third-to-market drug after Keytruda and Bristol-Myers Squibb’s Opdivo has just a fraction of their sales. Roche is … [Read more...] about Roche, chasing Merck, notches another lung cancer win